← IndicationsOpen filtered programs
Landscape
Sudden Hearing Loss
Sudden Hearing Loss has 8 tracked records across 3 named organizations, including 0 strong-evidence records and 5 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
8
Pipeline Records
strong evidence + caveats + candidates
0
Strong Evidence
8 checked records with caveats
5
Active Programs
currently active
0
Marketed / Approved
commercial or approved
3
Organizations
companies, sponsors, and institutions
Competitive Density
11/100
organization breadth + program volume
Pipeline Velocity
51/100
active and late-stage share
Evidence Coverage
0/100
share strong evidence
Completion Signal
25/100
late-stage, approved, or marketed
Attrition Rate
0/100
share discontinued
Concentration
75/100
top-organization share
Programs by Stage
Phase 12 · 25%
Phase 22 · 25%
Phase 32 · 25%
Not applicable2 · 25%
Trial / Program Status
Active5 · 63%
Paused1 · 13%
Unknown2 · 25%
Modality Breakdown
Small Molecule3 · 38%
Steroid/Anti-inflammatory3 · 38%
Cell Therapy1 · 13%
Regenerative Medicine1 · 13%
Program Types
Therapeutic8 · 100%
Top Organizations
Institution-led study6 · 75%
Phafag AG1 · 13%
Truway Health, Inc.1 · 13%
Population Tags
adult8 · 100%
sensorineural5 · 63%
sudden5 · 63%
tinnitus3 · 38%
sudden-hearing-loss2 · 25%
autologous1 · 13%
cell-derived-vesicles1 · 13%
combination-study1 · 13%
extracellular-vesicles1 · 13%
inner-ear-disease1 · 13%
Strong-Evidence Programs
0 recordsNo strong-evidence records yet for this indication.
Checked Records With Caveats
8 recordsIntratympanic dexamethasone versus methylprednisolone sudden-hearing-loss studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Unknown
Steroid/Anti-inflammatoryNot applicableUnknown84% confidence
Oral versus intratympanic glucocorticoid ISSNHL vestibular prognosis studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Unknown
Steroid/Anti-inflammatoryNot applicableUnknown84% confidence
AP-HP SERORL aspirin and folic acid SSNHL studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 3 · Active
Small MoleculePhase 3Active82% confidence
Fudan intracochlear glucocorticoid SSNHL studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Active
Steroid/Anti-inflammatoryPhase 2Active82% confidence
Transtympanic caroverine by PhafagStatus caveat
Company: Phafag AG · Phase 3 · Paused
Small MoleculePhase 3Paused80% confidence
Chang Gung hydroxychloroquine adjunct SSNHL studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Active
Small MoleculePhase 2Active80% confidence
Sun Yat-sen autologous monocyte vesicles sudden deafness studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1 · Active
Cell TherapyPhase 1Active80% confidence
Truway Health HEAR-RESTORE exploratory inner-ear regenerative studyStatus caveat
Company: Truway Health, Inc. · Phase 1 · Active
Regenerative MedicinePhase 1Active68% confidence